JP2002509692A - アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害 - Google Patents

アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害

Info

Publication number
JP2002509692A
JP2002509692A JP2000510858A JP2000510858A JP2002509692A JP 2002509692 A JP2002509692 A JP 2002509692A JP 2000510858 A JP2000510858 A JP 2000510858A JP 2000510858 A JP2000510858 A JP 2000510858A JP 2002509692 A JP2002509692 A JP 2002509692A
Authority
JP
Japan
Prior art keywords
seq
antisense
cells
hpv
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000510858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002509692A5 (https=
Inventor
ディパオロ，ジョセフ
アルバレス−サラス，ルイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2002509692A publication Critical patent/JP2002509692A/ja
Publication of JP2002509692A5 publication Critical patent/JP2002509692A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2000510858A 1997-09-05 1998-09-03 アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害 Withdrawn JP2002509692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/929,140 US6084090A (en) 1997-09-05 1997-09-05 Human papilloma virus anti-sense oligonucleotides
US08/929,140 1997-09-05
PCT/US1998/018320 WO1999013071A1 (en) 1997-09-05 1998-09-03 Human papilloma virus inhibition by anti-sense oligonucleotides

Publications (2)

Publication Number Publication Date
JP2002509692A true JP2002509692A (ja) 2002-04-02
JP2002509692A5 JP2002509692A5 (https=) 2006-01-05

Family

ID=25457385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510858A Withdrawn JP2002509692A (ja) 1997-09-05 1998-09-03 アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害

Country Status (7)

Country Link
US (2) US6084090A (https=)
EP (2) EP1595954A1 (https=)
JP (1) JP2002509692A (https=)
KR (1) KR100604218B1 (https=)
AU (1) AU9218398A (https=)
CA (1) CA2302148A1 (https=)
WO (1) WO1999013071A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1353935A4 (en) * 2000-12-07 2005-02-23 Penn State Res Found SELECTION OF TARGET CATALYTIC NUCLEIC ACIDS ON INFECTIOUS AGENTS
DE10154831A1 (de) * 2001-11-08 2003-06-05 Deutsches Krebsforsch PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen
US7704965B2 (en) * 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040248085A1 (en) * 2002-11-29 2004-12-09 Sang-Wha Lee General primers and process for detecting diverse genotypes of human papillomavirus by PCR
GB0500999D0 (en) * 2005-01-18 2005-02-23 Glaxosmithkline Biolog Sa Detection method and materials therefor
KR101197627B1 (ko) 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
KR102129852B1 (ko) * 2016-10-11 2020-07-24 주식회사 인코드젠 Rna 간섭 유도 핵산 및 이를 포함하는 hpv 감염 유발 암의 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
AU687492B2 (en) * 1993-11-16 1998-02-26 Genta Incorporated Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
US5683902A (en) * 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5580967A (en) * 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides

Also Published As

Publication number Publication date
EP1009823A1 (en) 2000-06-21
AU9218398A (en) 1999-03-29
WO1999013071A1 (en) 1999-03-18
EP1595954A1 (en) 2005-11-16
CA2302148A1 (en) 1999-03-18
US6084090A (en) 2000-07-04
KR20010015573A (ko) 2001-02-26
KR100604218B1 (ko) 2006-07-25
US6277980B1 (en) 2001-08-21

Similar Documents

Publication Publication Date Title
US5885834A (en) Antisense oligodeoxynucleotide against phosphodiesterase
CA2210353C (en) Stabilized external guide sequences
Brysch et al. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents
CA2436519A1 (en) Selection of catalytic nucleic acids targeted to infectious agents
EP1135482B1 (en) Cancer cell vaccine
WO1996021471A1 (en) Compositions and methods for treating tumor cells
CN108175862A (zh) 靶向连接蛋白的反义化合物及其使用方法
JPH1052264A (ja) Ｎ‐ｒａｓ発現阻害剤およびその方法
WO1992000080A1 (en) Method for treating leukemias
US20010010899A1 (en) Hpv-specific oligonucleotides
Alt et al. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation
JP2002509692A (ja) アンチセンスオリゴヌクレオチドによるヒト乳頭腫ウイルスの阻害
KR20200127211A (ko) Gys2 발현을 억제하기 위한 조성물 및 방법
CA2226457C (en) Oligonucleotides specific for human papilloma virus
US20010044145A1 (en) Methods of using mammalian RNase H and compositions thereof
US6656731B1 (en) Nucleic acid catalysts with endonuclease activity
Boiziau et al. A phosphorothioate oligonucleotide blocks reverse transcription via an antisense mechanism
EP1331267A2 (en) Oligonucleotides specific for hepatitis C virus
Kiely Recent advances in antisense technology
Prins et al. Antisense of oligonucleotides and the inhibition of oncogene expression
AU2002300401B2 (en) Human papilloma virus anti-sense oligonucleotides
Zhu et al. Antisense oligodeoxynucleotide inhibits expression of recombinant porcine follicle‐stimulating hormone receptor
Scalzitti et al. [6] Design and efficacy of serotonin-2A receptor antisense oligodeoxynucleotide
US20030055240A1 (en) HPV specific oligonucleotides
JP2003518952A (ja) ｂｃｌ−ｘＬの発現を特異的にダウンレギュレートするＥＧＳ分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050902

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071105